Clinical Trials Logo

Clinical Trial Summary

The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression of CD20 on leukemic cells the efficacy and tolerability of additional application of Rituximab together with chemotherapy is evaluated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00198978
Study type Interventional
Source Goethe University
Contact
Status Completed
Phase Phase 4
Start date January 2003
Completion date June 2014

See also
  Status Clinical Trial Phase
Completed NCT00199056 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Phase 4
Completed NCT00199043 - Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Phase 3
Completed NCT00199095 - Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Phase 4
Completed NCT00199108 - Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Phase 2/Phase 3
Completed NCT00199004 - Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Phase 4
Completed NCT00198991 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Phase 4
Completed NCT00199069 - German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Phase 4